Sichuan Kelun-Biotech jumps on approval for investigational new drug

Sichuan Kelun-Biotech Biopharmaceutical

18/06/2024 06:29

** Shares of Sichuan Kelun-Biotech Biopharmaceutical
 6990.HK  jump 4.8% to HK$180.5, their highest since June 11
    ** Stock on course for second session of gain; second
biggest pct gainer in Hong Kong's healthcare index  .HSCIH  
    ** Co says it has received clinical trial notice from the
National Medical Products Administration (NMPA) approving the
investigational new drug application for its drug SKB518 for
injection to treat advanced solid tumors 
    ** In accordance with the notice, co plans to organise and
implement a clinical trial of SKB518 for injection
    ** Hong Kong's healthcare index falls 1.7%, Hang Seng
Composite Index  .HSCI  slips 0.1% and Hang Seng Index  .HSI 
eases 0.2%
    ** Stock up 73.5% YTD  

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))